Elbasvir NEW
| Price | $37 | $51 | $76 |
| Package | 1mg | 2mg | 5mg |
| Supply Ability: | 10g |
| Update Time: | 2026-06-02 |
Product Details
| Product Name: Elbasvir | CAS No.: 1370468-36-2 |
| Purity: 99.93% | Supply Ability: 10g |
| Release date: 2026/06/02 |
Product Introduction
Bioactivity
| Name | Elbasvir |
| Description | Elbasvir (MK-8742) is an inhibitor of nonstructural protein 5A (NS5A) of hepatitis C virus (HCV) being developed as a component of treatment regimens for chronic HCV infection. |
| In vitro | Elbasvir potently inhibits hepatitis C virus (HCV) non-structural protein 5A (NS5A) with an EC50 value of 2.2 pM in Huh7 human liver cancer cells expressing pH77S.3/GLuc2A, a cell-culture adapted HCV16 genotype 1a derivative and luciferase reporter, following a 48-hour exposure in vitro [1,2]. NS5A is essential for HCV RNA synthesis and viral assembly, and elbasvir inhibits the assembly of new viral replicase complexes when used at a concentration of 50 pM [2]. It exhibits potent inhibitory activity against a broad range of HCV genotypes with EC50 values of 0.0002-34 nM in Huh7 cells expressing replicons of HCV genotype 4 NS5A and EC50 values of less than 0.2 nM for replicons from all other tested genotypes except 2b [1,3,4]. Formulations containing elbasvir have been used alone and in combination with NS3/4A protease inhibitors in the treatment of HCV. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+90% Saline : < 10 mg/mL (11.34 mM), Lower concentrations may be soluble, but exact solubility limit is unknown. DMSO : 125 mg/mL (141.72 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 10 mg/mL (11.34 mM), Solution. |
| Keywords | MK8742 | MK 8742 | Inhibitor | inhibit | Hepatitis C virus | HCVProtease | HCV Protease | HCV NS5A | HCV | Elbasvir |
| Inhibitors Related | EIDD-1931 | Methyl 2-amino-5-bromobenzoate | RO8191 | Sofosbuvir | Deferiprone | Ribavirin | Artemisinin | HCV-IN-29 | Honokiol | Chlorcyclizine | (Tetrahydro-2H-pyran-4-yl)methanol | Resiquimod |
| Related Compound Libraries | Bioactive Compound Library | Drug-induced Liver Injury (DILI) Compound Library | EMA Approved Drug Library | Anti-Viral Compound Library | Drug Repurposing Compound Library | Inhibitor Library | FDA-Approved Drug Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Infection Compound Library | Anti-COVID-19 Compound Library | Human Metabolite Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY